Avalo Therapeutics (AVTX)
Develops an anti-IL-1β antibody for immune-mediated inflammatory diseases.
Something off on this page? Send us feedback.
Develops abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody for immune-mediated inflammatory diseases. The clinical-stage business is concentrated on this lead program, acquired through AlmataBio.
Develops abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody, as its lead treatment candidate for immune-mediated inflammatory diseases. The clinical-stage business is fully dedicated to IL-1β-based treatments and reported positive Phase 2 LOTUS results in hidradenitis suppurativa, with a planned registrational Phase 3 study.
The 2024 AlmataBio acquisition brought abdakibart into the company, making it the central product and development focus. The issuer adopted the Avalo Therapeutics name and AVTX ticker in 2021. Headquartered in Wayne, Pennsylvania, it is a U.S.-listed clinical-stage business; its development path depends on clinical progress and the planned Phase 3 program.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 7, 2026 | Guggenheim | Reiterate | Buy | $50 | $48 |
| Aug 7, 2026 | H.C. Wainwright | Target | $35 | $30 | |
| Jul 6, 2026 | Leerink Partners | Target | $38 | ||
| May 14, 2026 | Wedbush | Reiterate | Outperform | $34 | |
| May 14, 2026 | Mizuho Securities | Target | $39 | $45 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $400.3M · Total debt $242.0K · Total assets $490.8M · Shareholders' equity $448.7M
- Revenue
- $0
- Operating income
- −$31.5M
- Net income
- −$36.4M
No dividends on record.
| Institutions109 holders · as of Mar 31, 2026 · largest filers plus last quarter's tail | ≈ 58.00% | 31.10M shares | |
| Insiders11 holders · as of Sep 1, 2026 | 0.71% | 381.1K shares | |
| Strategic holders1 holder · as of May 29, 2026 | 5.70% | 3.06M shares | |
| Otherremainder | ≈ 35.59% | 19.09M shares |
53.63M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Deep Track Capital, LPStrategic | 5.70% | 3.06M | 13Gfiled May 29, 2026 ↗ |
FMR LLCInstitution | 5.37% | 2.88M | 13Fas of Mar 31, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 4.03% | 2.16M | 13Fas of Mar 31, 2026 |
Caligan Partners LPInstitution | 3.05% | 1.64M | 13Fas of Mar 31, 2026 |
BVF Inc/ILInstitution | 3.04% | 1.63M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 28, 2026 | Mittie Doyle | officer: Chief Medical Officer | −679 | $20.00 |
| Aug 17, 2026 | Mittie Doyle | officer: Chief Medical Officer | −1,000 | $20.00 |
| Aug 18, 2026 | Christopher Ryan Sullivan | officer: Chief Financial Officer | −31,031 | $20.05 |
| Aug 17, 2026 | Christopher Ryan Sullivan | officer: Chief Financial Officer | −41,694 | $19.86 |
| Aug 10, 2026 | Mittie Doyle | officer: Chief Medical Officer | −679 | $20.00 |
- AbbVie
FDA-approved anti-TNF therapy and IL-1α/β Phase 3 contender in HS
- Novartis (ADR)
FDA-approved IL-17A biologic for adult moderate-to-severe HS
- MoonLake Immunotherapeutics
Phase 3 IL-17A/IL-17F Nanobody program pursuing an HS BLA
- Incyte
Phase 3 oral selective JAK1 program in moderate-to-severe HS
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Avalo Therapeutics | $19.35 | −0.05% | $1.02B | — | — | 17,230.8 | −58.6% |
| AbbVie | $264.00 | +0.88% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| MoonLake Immunotherapeutics | $15.02 | −0.33% | $1.27B | — | — | — | — |
| Incyte | $128.82 | +3.05% | $26.11B | 16.4 | 53.4 | 4.5 | +37.7% |
| Median | 24.5 | 17.3 | 5.6 | +10.2% |